NASDAQ:MESO - Mesoblast Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.77 +0.08 (+1.41 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$5.77
Today's Range$5.6680 - $5.78
52-Week Range$4.74 - $9.64
Volume14,261 shs
Average Volume25,129 shs
Market Capitalization$543.37 million
P/E Ratio-5.95
Dividend YieldN/A
Beta1.96

About Mesoblast (NASDAQ:MESO)

Mesoblast logoMesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MESO
CUSIPN/A
Phone61-3-9639-6036

Debt

Debt-to-Equity RatioN/A
Current Ratio3.35
Quick Ratio3.35

Price-To-Earnings

Trailing P/E Ratio-5.95
Forward P/E Ratio-11.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.41 million
Price / Sales225.46
Cash FlowN/A
Price / CashN/A
Book Value$6.03 per share
Price / Book0.96

Profitability

EPS (Most Recent Fiscal Year)($0.97)
Net Income$-76,810,000.00
Net Margins-188.83%
Return on Equity-9.78%
Return on Assets-8.03%

Miscellaneous

EmployeesN/A
Outstanding Shares94,170,000

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How were Mesoblast's earnings last quarter?

Mesoblast limited (NASDAQ:MESO) announced its earnings results on Tuesday, February, 27th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.09. The business earned $13.40 million during the quarter, compared to the consensus estimate of $0.34 million. Mesoblast had a negative net margin of 188.83% and a negative return on equity of 9.78%. View Mesoblast's Earnings History.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release their next quarterly earnings announcement on Wednesday, May, 30th 2018. View Earnings Estimates for Mesoblast.

What price target have analysts set for MESO?

5 analysts have issued 12-month price targets for Mesoblast's stock. Their predictions range from $6.00 to $23.00. On average, they expect Mesoblast's share price to reach $15.00 in the next year. View Analyst Ratings for Mesoblast.

What are Wall Street analysts saying about Mesoblast stock?

Here are some recent quotes from research analysts about Mesoblast stock:
  • 1. Maxim Group analysts commented, "Mesoblast reported changes to its cash position for the December quarter (FY: June 30), with a net cash outflow from operations of just $14M; this includes a €5M upfront payment from TiGenix (TIG.O – NR). Mesoblast ended the period with $47M in cash and has a $90M equity facility in place." (1/31/2018)
  • 2. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (1/23/2018)
  • 3. Cantor Fitzgerald analysts commented, "Heart Failure Holds Focus. In C1Q18, we expect top-line results of the Phase 2b, 159-patient, end-stage heart failure and LVAD study. We anticipate that disclosure of the top-line data on patient functional status (LVAD weaning) will remain limited until overall survival results (up to 12 months) become available. A successful outcome could accelerate the regulatory path of the overall cardiac program, in our view, especially considering recently awarded RMAT designation for the LVAD program." (1/16/2018)

Who are some of Mesoblast's key competitors?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 61)
  • Mr. Paul Hodgkinson MA (Hons), FCA, Chief Financial Officer (Age 50)
  • Dr. Suzanne Lipe BSc (Hons), Ph.D., LLB, VP of Operations (Age 68)
  • Mr. Jonathan Richard Symonds, Head of Corp. Fin. & Strategy (Age 59)
  • Mr. Peter Howard BSc, LLB (Hons), Gen. Counsel & Corp. Exec. (Age 50)

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Has Mesoblast been receiving favorable news coverage?

Press coverage about MESO stock has trended somewhat positive on Sunday, Accern reports. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mesoblast earned a media sentiment score of 0.03 on Accern's scale. They also gave press coverage about the company an impact score of 46.86 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Princeton Capital Management LLC (0.16%) and Jane Street Group LLC (0.02%). View Institutional Ownership Trends for Mesoblast.

Which major investors are buying Mesoblast stock?

MESO stock was purchased by a variety of institutional investors in the last quarter, including Princeton Capital Management LLC and Jane Street Group LLC. View Insider Buying and Selling for Mesoblast.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $5.77.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $543.37 million and generates $2.41 million in revenue each year. The company earns $-76,810,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]


MarketBeat Community Rating for Mesoblast (MESO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  288
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MESO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MESO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mesoblast (NASDAQ:MESO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Mesoblast in the last 12 months. Their average twelve-month price target is $15.00, suggesting that the stock has a possible upside of 159.97%. The high price target for MESO is $23.00 and the low price target for MESO is $6.00. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.672.67
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.00$15.00$14.75$14.25
Price Target Upside: 159.97% upside160.42% upside172.64% upside163.89% upside

Mesoblast (NASDAQ:MESO) Consensus Price Target History

Price Target History for Mesoblast (NASDAQ:MESO)

Mesoblast (NASDAQ:MESO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018Maxim GroupSet Price TargetBuy$14.00LowView Rating Details
3/22/2018Credit Suisse GroupDowngradeNeutral ➝ Underperform$6.00MediumView Rating Details
2/27/2018Cantor FitzgeraldSet Price TargetBuy ➝ Buy$20.00 ➝ $23.00HighView Rating Details
12/20/2017OppenheimerSet Price TargetBuy$16.00LowView Rating Details
8/31/2017CIBCInitiated CoverageOutperform ➝ Outperform$16.00HighView Rating Details
4/3/2017ScotiabankReiterated RatingHold$8.50LowView Rating Details
6/15/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Mesoblast (NASDAQ:MESO) Earnings History and Estimates Chart

Earnings by Quarter for Mesoblast (NASDAQ:MESO)

Mesoblast (NASDAQ:MESO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.59)
2019 EPS Consensus Estimate: ($0.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.20)($0.20)($0.20)
Q4 20181($0.20)($0.20)($0.20)
Q1 20191($0.20)($0.20)($0.20)
Q2 20191($0.21)($0.21)($0.21)
Q3 20191($0.23)($0.23)($0.23)
Q4 20191$0.05$0.05$0.05

Mesoblast (NASDAQ MESO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/30/2018        
2/27/2018Q2 2018($0.19)($0.10)$0.34 million$13.40 millionViewN/AView Earnings Details
11/14/2017Q1 2018($0.23)($0.08)$0.34 million$1.17 millionViewN/AView Earnings Details
8/29/2017Q4 2017($0.32)$0.57 millionViewN/AView Earnings Details
5/24/2017Q3 2017($0.12)$0.90 millionViewN/AView Earnings Details
2/26/2017Q2 2017($0.26)$0.55 millionViewN/AView Earnings Details
11/14/2016Q1 2017($0.26)$0.40 millionViewN/AView Earnings Details
8/25/2016Q4 2016$1.17$26.88 millionViewN/AView Earnings Details
5/9/2016Q3 2016($0.22)$4.14 millionViewN/AView Earnings Details
2/16/2016Q2 2016($0.31)$11.80 million$4.01 millionViewN/AView Earnings Details
12/17/2015Q1 2016($0.20)$7.51 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Mesoblast (NASDAQ:MESO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mesoblast (NASDAQ MESO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.80%
Institutional Ownership Percentage: 2.95%
Insider Trading History for Mesoblast (NASDAQ:MESO)
Institutional Ownership by Quarter for Mesoblast (NASDAQ:MESO)

Mesoblast (NASDAQ MESO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Mesoblast (NASDAQ MESO) News Headlines

Source:
DateHeadline
Mesoblast (MESO) Receives Average Recommendation of "Hold" from BrokeragesMesoblast (MESO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 15 at 5:34 AM
Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell ...Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell ...
globenewswire.com - May 8 at 3:02 PM
Form 6-K MESOBLAST LTD For: May 04Form 6-K MESOBLAST LTD For: May 04
www.streetinsider.com - May 4 at 3:13 PM
Mesoblast Aims For Non-Addictive Opioid Substitute: CEO IMesoblast Aims For Non-Addictive Opioid Substitute: CEO I
www.bloomberg.com - April 26 at 5:00 AM
Facebook Tries to Curb Fake News, Abuse with New GuidelinesFacebook Tries to Curb Fake News, Abuse with New Guidelines
www.bloomberg.com - April 25 at 3:10 PM
Who Just Ramped Up Their Shares In Mesoblast Limited (ASX:MSB)?Who Just Ramped Up Their Shares In Mesoblast Limited (ASX:MSB)?
finance.yahoo.com - April 24 at 5:12 AM
Mesoblast (MESO) Receives Consensus Recommendation of "Hold" from AnalystsMesoblast (MESO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 20 at 5:35 AM
BidaskClub Downgrades Mesoblast (MESO) to SellBidaskClub Downgrades Mesoblast (MESO) to Sell
www.americanbankingnews.com - April 18 at 5:48 PM
TiGenix reports 2017 full year resultsTiGenix reports 2017 full year results
feeds.benzinga.com - April 12 at 3:14 AM
Mesoblasts (MESO) Buy Rating Reiterated at Cantor FitzgeraldMesoblast's (MESO) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 9 at 7:30 PM
Credit Suisse Downgrades Mesoblast Limited (MESO) to Underperform, Cautious heading into upcoming heart failure readoutCredit Suisse Downgrades Mesoblast Limited (MESO) to Underperform, 'Cautious heading into upcoming heart failure readout'
www.streetinsider.com - April 7 at 5:13 AM
Mesoblast (MESO) Stock Rating Lowered by Zacks Investment ResearchMesoblast (MESO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 2 at 5:52 PM
Market Sentiment Around Loss-Making Mesoblast Limited (ASX:MSB)Market Sentiment Around Loss-Making Mesoblast Limited (ASX:MSB)
finance.yahoo.com - March 31 at 5:10 AM
Form 6-K MESOBLAST LTD For: Mar 29Form 6-K MESOBLAST LTD For: Mar 29
www.streetinsider.com - March 30 at 3:12 PM
Maxim Group Reiterates "$14.00" Price Target for Mesoblast (MESO)Maxim Group Reiterates "$14.00" Price Target for Mesoblast (MESO)
www.americanbankingnews.com - March 29 at 9:18 AM
Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes EnrollmentMesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment
finance.yahoo.com - March 29 at 5:07 AM
Cantor Fitzgerald Analysts Give Mesoblast (MESO) a $20.00 Price TargetCantor Fitzgerald Analysts Give Mesoblast (MESO) a $20.00 Price Target
www.americanbankingnews.com - March 28 at 4:25 PM
Mesoblast limited (MESO) Given Consensus Recommendation of "Hold" by BrokeragesMesoblast limited (MESO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 26 at 5:41 AM
Cantor Fitzgerald Analysts Give Mesoblast (MESO) a $23.00 Price TargetCantor Fitzgerald Analysts Give Mesoblast (MESO) a $23.00 Price Target
www.americanbankingnews.com - March 24 at 5:43 PM
Mesoblast (MESO) Downgraded to Underperform at Credit Suisse GroupMesoblast (MESO) Downgraded to Underperform at Credit Suisse Group
www.americanbankingnews.com - March 22 at 10:22 PM
Benzingas Top Upgrades, Downgrades For March 22, 2018 - BenzingaBenzinga's Top Upgrades, Downgrades For March 22, 2018 - Benzinga
www.benzinga.com - March 22 at 3:13 PM
Mesoblasts Delayed Launches, Teva Split Turn Credit Suisse Bearish - BenzingaMesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish - Benzinga
www.benzinga.com - March 22 at 3:13 PM
Credit Suisse Downgrades Mesoblast Limited (MESO) to Underperform, Cautious heading into upcoming heart failure ... - StreetInsider.comCredit Suisse Downgrades Mesoblast Limited (MESO) to Underperform, 'Cautious heading into upcoming heart failure ... - StreetInsider.com
www.streetinsider.com - March 22 at 3:13 PM
Contrasting Mesoblast (MESO) & AC Immune (ACIU)Contrasting Mesoblast (MESO) & AC Immune (ACIU)
www.americanbankingnews.com - March 18 at 3:13 PM
Maxim Group Analysts Give Mesoblast (MESO) a $14.00 Price TargetMaxim Group Analysts Give Mesoblast (MESO) a $14.00 Price Target
www.americanbankingnews.com - March 7 at 4:15 PM
Mesoblast Enters Into US$75 Million Non-Dilutive Credit FacilityMesoblast Enters Into US$75 Million Non-Dilutive Credit Facility
finance.yahoo.com - March 7 at 5:18 AM
Mesoblast limiteds medical treatment passes Phase III trials - Motley Fool AustraliaMesoblast limited's medical treatment passes Phase III trials - Motley Fool Australia
www.fool.com.au - March 6 at 6:31 AM
Mesoblast limited Forecasted to Earn FY2018 Earnings of ($0.38) Per Share (MESO)Mesoblast limited Forecasted to Earn FY2018 Earnings of ($0.38) Per Share (MESO)
www.americanbankingnews.com - March 5 at 5:22 AM
Oppenheimer Comments on Mesoblast limiteds Q3 2018 Earnings (MESO)Oppenheimer Comments on Mesoblast limited's Q3 2018 Earnings (MESO)
www.americanbankingnews.com - March 2 at 11:32 AM
Mesoblast limited (MESO) Expected to Earn Q4 2019 Earnings of $0.05 Per ShareMesoblast limited (MESO) Expected to Earn Q4 2019 Earnings of $0.05 Per Share
www.americanbankingnews.com - March 1 at 3:46 PM
Mesoblast limited (MESO) Receives Consensus Recommendation of "Hold" from AnalystsMesoblast limited (MESO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 1 at 5:30 AM
Mesoblast (MESO) Given a $14.00 Price Target at Maxim GroupMesoblast (MESO) Given a $14.00 Price Target at Maxim Group
www.americanbankingnews.com - February 28 at 6:54 PM
Mesoblast Operational Highlights and Financial Results for the Half ... - GlobeNewswire (press release)Mesoblast Operational Highlights and Financial Results for the Half ... - GlobeNewswire (press release)
globenewswire.com - February 28 at 5:10 AM
Mesoblast Operational Highlights and Financial Results for the Half-Year Ended December 31, 2017Mesoblast Operational Highlights and Financial Results for the Half-Year Ended December 31, 2017
finance.yahoo.com - February 28 at 5:10 AM
Form 6-K MESOBLAST LTD For: Feb 27 - StreetInsider.comForm 6-K MESOBLAST LTD For: Feb 27 - StreetInsider.com
www.streetinsider.com - February 27 at 3:10 PM
Head to Head Review: Mesoblast (MESO) vs. CASI Pharmaceuticals (CASI)Head to Head Review: Mesoblast (MESO) vs. CASI Pharmaceuticals (CASI)
www.americanbankingnews.com - February 25 at 11:10 PM
Mesoblast (MESO) PT Set at $20.00 by Cantor FitzgeraldMesoblast (MESO) PT Set at $20.00 by Cantor Fitzgerald
www.americanbankingnews.com - February 25 at 1:36 PM
Your Daily Pharma Scoop: Clovis Oncology Gets A Boost, Mesoblast Positive Data, Kadmons Updated Results - Seeking AlphaYour Daily Pharma Scoop: Clovis Oncology Gets A Boost, Mesoblast Positive Data, Kadmon's Updated Results - Seeking Alpha
seekingalpha.com - February 24 at 3:08 PM
Mesoblasts MSC-100-IV successful in late-stage GvHD study; shares ahead 11% premarket - Seeking AlphaMesoblast's MSC-100-IV successful in late-stage GvHD study; shares ahead 11% premarket - Seeking Alpha
seekingalpha.com - February 22 at 3:13 PM
Primary Endpoint Successfully Achieved in Mesoblasts Phase 3 ... - GlobeNewswire (press release)Primary Endpoint Successfully Achieved in Mesoblast's Phase 3 ... - GlobeNewswire (press release)
globenewswire.com - February 22 at 5:13 AM
Primary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host DiseasePrimary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease
finance.yahoo.com - February 22 at 5:13 AM
Mesoblast stem cell therapy meets goal of pediatric Graft vs Host studyMesoblast stem cell therapy meets goal of pediatric Graft vs Host study
finance.yahoo.com - February 22 at 5:13 AM
Is Mesoblast Limited’s (ASX:MSB) CEO Pay Fair?Is Mesoblast Limited’s (ASX:MSB) CEO Pay Fair?
finance.yahoo.com - February 20 at 5:13 AM
Breaking Down Mesoblast Limited’s (ASX:MSB) Ownership StructureBreaking Down Mesoblast Limited’s (ASX:MSB) Ownership Structure
finance.yahoo.com - February 12 at 5:01 AM
Mesoblast limited (MESO) Receives Consensus Rating of "Hold" from AnalystsMesoblast limited (MESO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 4 at 5:30 AM
What Is The Future Prospect For Healthcare And Mesoblast Limited (ASX:MSB)?What Is The Future Prospect For Healthcare And Mesoblast Limited (ASX:MSB)?
finance.yahoo.com - February 3 at 5:05 AM
Mesoblast (MESO) Receives "Buy" Rating from Maxim GroupMesoblast (MESO) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - January 31 at 12:10 PM
Mesoblast (MESO): 1Q18 Phase III Pediatric GvHD Data - Ladenberg - StreetInsider.comMesoblast (MESO): 1Q18 Phase III Pediatric GvHD Data - Ladenberg - StreetInsider.com
www.streetinsider.com - January 26 at 3:01 PM
Mesoblast (MESO) Lowered to Hold at Zacks Investment ResearchMesoblast (MESO) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 23 at 6:12 AM
Mesoblast (MESO) Raised to Buy at Zacks Investment ResearchMesoblast (MESO) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - January 13 at 10:54 AM

SEC Filings

Mesoblast (NASDAQ:MESO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Mesoblast (NASDAQ MESO) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.